The HER2-positive (any ER) subtype accounted for 20.5% in Ethiopia and 26.7% in Sweden, while triple-negative breast cancer accounted for 11.5% (Ethiopia) and 25.7% (Sweden). This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.